2. Academic Validation
  3. Discovery of a novel nonsteroidal selective glucocorticoid receptor modulator by virtual screening and bioassays

Discovery of a novel nonsteroidal selective glucocorticoid receptor modulator by virtual screening and bioassays

  • Acta Pharmacol Sin. 2022 Sep;43(9):2429-2438. doi: 10.1038/s41401-021-00855-6.
Jin-Ping Pang  # 1,  Xue-Ping Hu  # 1,  Yun-Xia Wang 1,  Jia-Ning Liao 1,  Xin Chai 1,  Xu-Wen Wang 1,  Chao Shen 1,  Jia-Jia Wang 2,  Lu-Lu Zhang 2,  Xin-Yue Wang 1,  Feng Zhu 1,  Qin-Jie Weng 2,  Lei Xu 3,  Ting-Jun Hou 1 4,  Dan Li 5
Affiliations

Affiliations

  • 1 Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
  • 2 State Key Lab of CAD&CG, Zhejiang University, Hangzhou, 310058, China.
  • 3 Institute of Bioinformatics and Medical Engineering, School of Electrical and Information Engineering, Jiangsu University of Technology, Changzhou, 213001, China.
  • 4 Center for Drug Safety Evaluation and Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
  • 5 Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China. lidancps@zju.edu.cn.
  • # Contributed equally.
PMID: 35110698 DOI: 10.1038/s41401-021-00855-6
Abstract

Synthetic glucocorticoids (GCs) have been widely used in the treatment of a broad range of inflammatory diseases, but their clinic use is limited by undesired side effects such as metabolic disorders, osteoporosis, skin and muscle atrophies, mood disorders and hypothalamic-pituitary-adrenal (HPA) axis suppression. Selective Glucocorticoid Receptor modulators (SGRMs) are expected to have promising anti-inflammatory efficacy but with fewer side effects caused by GCs. Here, we reported HT-15, a prospective SGRM discovered by structure-based virtual screening (VS) and bioassays. HT-15 can selectively act on the NF-κB/AP1-mediated transrepression function of Glucocorticoid Receptor (GR) and repress the expression of pro-inflammation cytokines (i.e., IL-1β, IL-6, COX-2, and CCL-2) as effectively as dexamethasone (Dex). Compared with Dex, HT-15 shows less transactivation potency that is associated with the main adverse effects of synthetic GCs, and no cross activities with Other nuclear receptors. Furthermore, HT-15 exhibits very weak inhibition on the ratio of OPG/RANKL. Therefore, it may reduce the side effects induced by normal GCs. The bioactive compound HT-15 can serve as a starting point for the development of novel therapeutics for high dose or long-term anti-inflammatory treatment.

Keywords

SGRMs; anti-inflammation; glucocorticoid receptor; transrepression.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z